Want to join the conversation?
$VRTX 2Q15 Call: Global sales of KALYDECO this quarter were $155MM, comprised of US sales of approx. $93MM and ex-US sales of approx. $62MM. The company has seen good uptake in patients with R117H mutation following approval in US in late 2014, and in children ages 2-5 with eligible mutations following US approval at the end of March 2015.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)